Short Interest in Clinuvel Pharmaceuticals Limited (OTCMKTS:CLVLY) Rises By 1,300.0%

Clinuvel Pharmaceuticals Limited (OTCMKTS:CLVLY) was the recipient of a large increase in short interest in November. As of November 15th, there was short interest totalling 2,800 shares, an increase of 1,300.0% from the October 31st total of 200 shares. Based on an average trading volume of 5,400 shares, the short-interest ratio is currently 0.5 days.

Clinuvel Pharmaceuticals Stock Performance

Clinuvel Pharmaceuticals stock traded up $0.01 during midday trading on Wednesday, reaching $8.50. 6,502 shares of the stock traded hands, compared to its average volume of 2,783. The company has a 50-day simple moving average of $9.36 and a two-hundred day simple moving average of $9.68. Clinuvel Pharmaceuticals has a 12-month low of $8.00 and a 12-month high of $12.06.

Clinuvel Pharmaceuticals Increases Dividend

The firm also recently announced a dividend, which was paid on Monday, September 30th. Investors of record on Monday, September 9th were paid a dividend of $0.0299 per share. This is an increase from Clinuvel Pharmaceuticals’s previous dividend of $0.03. The ex-dividend date was Monday, September 9th.

About Clinuvel Pharmaceuticals

Clinuvel Pharmaceuticals Limited, a biopharmaceutical company, focuses on developing and commercializing treatments for patients with genetic, metabolic, and life-threatening disorders in Australia, Europe, the United States, Switzerland, and internationally. Its lead drug candidate is SCENESSE, a systemic photoprotective drug for the prevention of phototoxicity in adult patients with erythropoietic protoporphyria (EPP).